AGC has completed the expansion of its production facility in Denmark, the company writes in a press release.

The expansion entailed an additional 19,000 square meters including a production hall, quality control and warehouse, has cost around DKK 1.3bn (USD 190m) and increases the contract manufacturer’s capacity to produce drugs based on mammalian cells. It also allows for the production of an additional 150 batches of medicine each year. 

”AGC Biologics Copenhagen site continues to be one of the most active in our network with all the necessary commercial approvals,” Christoph Winterhalter, chief business officer at AGC, said in the announcement.

The new manufacturing capabilities have already been commissioned by the first customer to have a product manufactured for Phase II/III testing at the contract manufacturer in Denmark. 

AGC Biologics was formed through a DKK 3.5bn (USD 510m) merger of Japanese AGC Asahi Glass and Danish-American CMC Biologics. 

CMC Biologics was started in Denmark in 2001 by a number of spin-offs from Novo Nordisk and Novozymes.

English edit: Catherine Brett